6 citations
,
July 2025 in “Cancer Medicine” This study reported that ZSYY001, a nanoparticle formulation of polymeric micellar paclitaxel, showed promising antitumor activity and was safe and well-tolerated in preclinical models and a phase I trial, without acute hypersensitivity reactions at doses up to 390 mg/m².
3 citations
,
February 2023 in “Journal of drug delivery science and technology” In vitro, this study found that PTX and HU SF-FA NLCs showed greater cytotoxicity and apoptosis in ovarian cancer cells than pure paclitaxel, suggesting promise as a targeted drug delivery platform.
April 2026 in “bioRxiv (Cold Spring Harbor Laboratory)” This study introduced hydrogel microneedles loaded with palladium nanoparticles, which utilize the inherent cytotoxicity of polyethyleneimine to enhance the effectiveness of doxorubicin in treating melanoma, achieving a tumor inhibition rate of up to 98% in a murine model.
5 citations
,
June 2005 in “Journal of Clinical Oncology” This study found that paclitaxel poliglumex induces significantly less and milder alopecia compared with standard taxanes in ovarian and breast cancer patients.
9 citations
,
January 2021 in “BioMed research international” This study describes a method to extract and characterize keratin particles from human hair, finding they can encapsulate the anticancer drug Paclitaxel with significant efficiency, releasing it in a pH-dependent manner potentially beneficial for targeted cancer treatment.
